Increased Cholesterol Levels During Paroxetine Administration in Healthy Men
J Clin Psychiatry 2003;64(12):1455-1459
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Despite the frequent use of
selective serotonin reuptake inhibitors in patients with coronary
heart disease (CHD), their effects on plasma lipid levels have
not been systematically investigated. Our objective was to assess
the effects of 8 weeks of paroxetine administration on plasma
cholesterol and triglyceride levels.
Method: Blood samples were collected at
baseline, after 8 weeks of paroxetine administration, and
post-discontinuation in 18 healthy male volunteers.
Results: In the 16 of 18 patients whose plasma
levels of paroxetine indicated an unequivocal compliance to
treatment, paroxetine administration induced an 11.5% increase in
low-density lipoprotein cholesterol (LDL-C), which normalized
after paroxetine discontinuation.
Conclusion: The magnitude of the
paroxetine-induced increase in LDL-C would lead to a minor
increase in CHD risk in a minority of healthy male volunteers
without associated CHD risk factors but might increase LDL-C
sufficiently to warrant therapeutic intervention in patients with
established CHD, based on the National Cholesterol Education